BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38451524)

  • 1. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
    Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
    JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis.
    Wu Y; Hu L; Zhang S; Zhang H
    Technol Cancer Res Treat; 2024; 23():15330338241258164. PubMed ID: 38872482
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Liao PF; Wang PY; Peng TR
    Curr Oncol; 2023 Nov; 30(11):9940-9952. PubMed ID: 37999142
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis.
    Chen Y; Han H; Cheng J; Cheng Q; Zhu S; Zhan P; Liu H; Song Y; Lv T
    Cancer Immunol Immunother; 2024 Jun; 73(8):155. PubMed ID: 38834888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Programmed Death 1/Programmed Death-Ligand 1 Plus Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibitors for Advanced or Metastatic Non-Small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials.
    Ren W; Fang Y; He Y; Ren Y; Wang M; Xu A; Ruan J; Tao Q
    Ther Drug Monit; 2024 Jun; ():. PubMed ID: 38840327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Antibodies Plus Chemotherapy as First-Line Treatment for NSCLC in the People's Republic of China: a Systematic Review and Meta-Analysis.
    Chen QA; Ma K; Zhang L; Lin WH; Wu XX; Gao YB
    JTO Clin Res Rep; 2024 Jun; 5(6):100678. PubMed ID: 38846810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moving Immunotherapy Into the Treatment of Resectable Non-Small Cell Lung Cancer.
    Chaft JE; Dziadziuszko R; Haddock Lobo Goulart B
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432500. PubMed ID: 38788177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease.
    Sathiyapalan A; Baloush Z; Ellis PM
    Curr Oncol; 2023 Oct; 30(11):9514-9529. PubMed ID: 37999109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical status and perspective on the application of immunotherapy combined with chemotherapy in advanced non-small cell lung cancer: a review.
    Wang T; Zhang L; Cheng Y
    Chin Clin Oncol; 2024 Apr; 13(2):26. PubMed ID: 38600808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative Immunotherapy in Non-Small Cell Lung Cancer.
    O'Brien J; Bodor JN
    Curr Treat Options Oncol; 2023 Dec; 24(12):1790-1801. PubMed ID: 38091187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative Immune Checkpoint Blockade for Muscle-Invasive and Metastatic Bladder Cancer.
    Ramamurthy C; Wheeler KM; Trecarten S; Hassouneh Z; Ji N; Lee Y; Svatek RS; Mukherjee N
    J Cancer Immunol (Wilmington); 2024; 6(1):29-39. PubMed ID: 38784962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of neoadjuvant chemotherapy combined with surgery in patients with nonsmall cell lung cancer: A meta-analysis.
    Dong HJ; Yang CY
    Clin Respir J; 2024 May; 18(5):e13756. PubMed ID: 38725310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of different cycles of neoadjuvant immunotherapy in resectable non-small cell lung cancer: A systematic review and meta-analysis.
    Ye L; Liu Y; Xiang X; Wang Z; Peng W; Wei X; Zhang S; Xue Q; Zhou Q
    Heliyon; 2024 Jun; 10(11):e31549. PubMed ID: 38828349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysis.
    Waser NA; Quintana M; Schweikert B; Chaft JE; Berry L; Adam A; Vo L; Penrod JR; Fiore J; Berry DA; Goring S
    JNCI Cancer Spectr; 2024 Apr; 8(3):. PubMed ID: 38521542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta-analysis.
    Wu D; Yang L; Yan Y; Jiang Z; Liu Y; Dong P; Lv Y; Zhou S; Qiu Y; Yu X
    Cancer Med; 2024 May; 13(9):e7176. PubMed ID: 38716645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC.
    Mao Z; Pang G; Huang X; Chen X; Wu J; Xu X; Teng Z; Tan Y; Wang P
    BMC Pulm Med; 2024 May; 24(1):253. PubMed ID: 38783253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular Endothelial Growth Factor Receptor Inhibitors for Recurrent or Metastatic Adenoid Cystic Carcinoma: A Systematic Review and Meta-Analysis.
    Hoff CO; Manzi J; Lazar Neto F; Ferrarotto R
    JAMA Otolaryngol Head Neck Surg; 2024 May; ():. PubMed ID: 38814585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review.
    Efil SC; Bilgin B; Ceylan F; Karakaş H; Karahan İ; Özsan SN; Kosku H; Yaman Ş; Bülent Akıncı M; Dede DŞ; Yalçın B; Nahit Şendur MA
    J Oncol Pharm Pract; 2024 Jun; ():10781552241260864. PubMed ID: 38860323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine adverse events in patients with cancer receiving perioperative immune checkpoint blockade: a meta-analysis of randomized controlled trials.
    Zhou S; Horita N; Shao T; Harrington M; Fujiwara Y
    Ther Adv Med Oncol; 2024; 16():17588359241257874. PubMed ID: 38845790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant immunotherapy based on PD-1/L1 Inhibitors for gastrointestinal tumor: a review of rationale and clinical advances.
    Wang DX; Liu H; Tian JC; Zhang DL; Yan LJ; Ding ZN; Li H; Yan YC; Dong ZR; Li T
    Int J Surg; 2024 Mar; 110(6):3707-22. PubMed ID: 38518083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.